2017 Annual Meeting | PL1 - Hot Topics Plenary Session
| 05:00 PM - 05:20 PM | Speaker |
Lysosomal Proteins as a Therapeutic Target in Neurodegeneration
Dimitri Krainc, MD, PhD |
| 05:20 PM - 05:40 PM | Speaker |
Antisense Oligonucleotide Treatment (ASO) and SMA: Results of Clinical Trials
Claudia A. Chiriboga, MD, FAAN |
| 05:40 PM - 06:00 PM | Speaker |
The Role of CNS-draining Lymphatics in Neurological Diseases
Jonathan Kipnis, PhD |
| 06:00 PM - 06:20 PM | Speaker |
Population-based Comprehensive Epilepsy Care in Ontario, Canada: A Model Network
O. C. Snead III, MD, FAAN |
| Claudia A. Chiriboga, MD, FAAN | Dr. Chiriboga has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentec. Dr. Chiriboga has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Dr. Chiriboga has received research support from Roche. The institution of Dr. Chiriboga has received research support from Avexis/Novartis. The institution of Dr. Chiriboga has received research support from Biogen. The institution of Dr. Chiriboga has received research support from NIH. The institution of Dr. Chiriboga has received research support from Biohaven. The institution of Dr. Chiriboga has received research support from Genentec. Dr. Chiriboga has received publishing royalties from a publication relating to health care. |
| Jonathan Kipnis, PhD | No disclosure on file |
| Dimitri Krainc, MD, PhD | Dr. Krainc has nothing to disclose. |
| O. C. Snead III, MD, FAAN | Dr. Snead has nothing to disclose. |
| Eric Klawiter, MD, FAAN | Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Galen/Atlantica. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Banner Life Sciences. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Greenwich Biosciences. Dr. Klawiter has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for OM1. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Klawiter has received research support from Biogen. The institution of Dr. Klawiter has received research support from Abbvie. The institution of Dr. Klawiter has received research support from Genentech. |